In situ gene therapy for prostate cancer: immunomodulatory approaches.
about
Recent developments in oncolytic adenovirus-based immunotherapeutic agents for use against metastatic cancers.Cooperative effects of adenoviral vector-mediated interleukin 12 gene therapy with radiotherapy in a preclinical model of metastatic prostate cancer.Route of administration influences the antitumor effects of bone marrow-derived dendritic cells engineered to produce interleukin-12 in a metastatic mouse prostate cancer model.
P2860
In situ gene therapy for prostate cancer: immunomodulatory approaches.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
In situ gene therapy for prostate cancer: immunomodulatory approaches.
@ast
In situ gene therapy for prostate cancer: immunomodulatory approaches.
@en
In situ gene therapy for prostate cancer: immunomodulatory approaches.
@nl
type
label
In situ gene therapy for prostate cancer: immunomodulatory approaches.
@ast
In situ gene therapy for prostate cancer: immunomodulatory approaches.
@en
In situ gene therapy for prostate cancer: immunomodulatory approaches.
@nl
prefLabel
In situ gene therapy for prostate cancer: immunomodulatory approaches.
@ast
In situ gene therapy for prostate cancer: immunomodulatory approaches.
@en
In situ gene therapy for prostate cancer: immunomodulatory approaches.
@nl
P2093
P2860
P356
P1476
In situ gene therapy for prostate cancer: immunomodulatory approaches.
@en
P2093
Thompson TC
Wheeler TM
P2860
P304
P356
10.1517/14712598.1.3.481
P407
P577
2001-05-01T00:00:00Z